Arndt Vogel, MD

Arndt Vogel, MD, is a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre

Articles by Arndt Vogel, MD

Patient Profile 1: Resection for Early/Intermediate Stage HCC

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

ByArndt Vogel, MD

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma

ByArndt Vogel, MD

September 27th 2019

Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.

Arndt Vogel, MD

Articles by Arndt Vogel, MD

Patient Profile 1: Resection for Early/Intermediate Stage HCC

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026